OncoMatch/Clinical Trials/NCT06113302
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Is NCT06113302 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Luspatercept for myelodysplastic syndromes.
Treatment: Luspatercept — To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage LOW, INT-1 (IPSS or IPSS-R)
low or int-1 risk by IPSS or a score of ≤ 3.5 by IPSS-R
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: luspatercept (luspatercept)
Prior treatment with luspatercept
Cannot have received: sotarcetept (sotarcetept)
Prior treatment with sotarcetept
Lab requirements
Blood counts
platelet count of ≤100 k/ul and/or anc of ≤1.8 k/ul
Kidney function
serum creatinine clearance ≥40ml/min and no end/stage renal disease (using cockcroft-gault)
Liver function
total bilirubin ≤3 x uln, ast or alt ≤3xuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify